Daily Archives

April 30, 2014

PrEP ÉCLAIR: An Exciting Possibility for the Future of PrEP

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute | No Comments
The HIV epidemic is continuing to grow worldwide. Because no single prevention intervention is a panacea, multiple prevention strategies should be evaluated and made available as combination interventions as quickly as possible, including agents for pre-exposure prophylaxis (PrEP) for both men and women. Oral tenofovir disproxil fumarate/emtricitabine (TDF/FTC) was approved by the Food and Drug Administration (FDA) for PrEP in July 2012. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have offered interim guidance about the use of TDF/FTC as PrEP. While the TDF/FTC combination provides an exciting new prevention tool, alternative PrEP agents 
Read More